Search Result
Results for "
disease
" in MedChemExpress (MCE) Product Catalog:
9864
Inhibitors & Agonists
101
Biochemical Assay Reagents
718
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-147108
-
|
Mitochondrial Metabolism
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease .
|
-
-
- HY-137431A
-
(R)-BAY-2433334
|
Others
|
Cardiovascular Disease
|
(R)-Asundexian ((R)-BAY-2433334) is the enantiomer of Asundexian (HY-137431). (R)-Asundexian can be used in studies of cardiovascular disease (especially thrombotic or thromboembolic disease), edema, and ophthalmic disease .
|
-
-
- HY-16743
-
Venglustat; SAR402671; GZ402671
|
Glucosylceramide Synthase (GCS)
|
Metabolic Disease
|
Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
|
-
-
- HY-N13380
-
-
-
- HY-P4040
-
-
-
- HY-153427
-
|
Tau Protein
|
Neurological Disease
|
Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .
|
-
-
- HY-161163
-
|
AMPK
|
Neurological Disease
|
IND 1316 is an orally active, blood-brain barrier permeable AMPK activator with neuroprotective effects in animal models of Huntington's disease. IND 1316 can be used for research on neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .
|
-
-
- HY-123485
-
|
Amyloid-β
|
Neurological Disease
|
PPI-1019 is an amyloid beta (Aβ) inhibitor. PPI-1019 can be used in the research of neurological diseases and Alzheimer's disease .
|
-
-
- HY-122105
-
|
Adenosine Receptor
|
Neurological Disease
|
JNJ-40255293 is a high-affinity human A 2A receptor antagonist with a KiKi of 7.5 nM. JNJ-40255293 can be used in the research of neurodegenerative diseases such as Parkinson's disease .
|
-
-
- HY-16743C
-
Venglustat hydrochloride; SAR402671 hydrochloride; GZ402671 hydrochloride
|
Glucosylceramide Synthase (GCS)
|
Metabolic Disease
|
Ibiglustat hydrochloride is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat hydrochloride can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
|
-
-
- HY-118284
-
|
P2Y Receptor
|
Cardiovascular Disease
|
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
|
-
-
- HY-147240
-
ADX-629
|
Others
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
Acloproxalap is a quinoline-based aldehyde scavenger that can be used in studies of diseases with toxic aldehyde accumulation, such as inflammatory diseases of the eye and skin, respiratory diseases such as pneumonia, organ diseases, and viral infection-related syndromes .
|
-
-
- HY-16743B
-
Venglustat succinate; SAR402671 succinate; GZ402671 succinate
|
Glucosylceramide Synthase (GCS)
|
Neurological Disease
|
Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
|
-
-
- HY-120611A
-
-
-
- HY-163689
-
-
-
- HY-16743A
-
Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)
|
Glucosylceramide Synthase (GCS)
|
Metabolic Disease
|
Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
|
-
-
- HY-147579
-
|
TAM Receptor
|
Infection
Inflammation/Immunology
Cancer
|
Axl-IN-12 (Example 2) is a potent AXL inhibitor. Axl-IN-12 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .
|
-
-
- HY-150018
-
|
mAChR
|
Neurological Disease
|
N-Demethyl MK-6884 (compound 34) is a potent M4 mAChR allosteric modulator. N-Demethyl MK-6884 can be used in the studies of alzheimer's disease and other diseases mediated by the M4 mAChR .
|
-
-
- HY-120611
-
-
-
- HY-170487
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-38 (Compound 6b) is a reversible and competitive MAO-B inhibitor, with IC50 values of 0.03 and 21.46 µM for MAO-B and MAO-A, respectively. MAO-B-IN-38 can be used for the research of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases .
|
-
-
- HY-147578
-
|
TAM Receptor
|
Infection
Inflammation/Immunology
Cancer
|
Axl-IN-11 (Example 1) is a potent AXL inhibitor. Axl-IN-11 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .
|
-
-
- HY-119378
-
CX 295
|
Proteasome
Apoptosis
|
Neurological Disease
|
AK 295 (CX 295) is a calpain inhibitor that inhibits apoptosis through a calpain-dependent pathway. AK 295 improves neurological function in a rat model of spinal cord injury (SCI). AK 295 can be used in the study of neurodegenerative diseases, such as bulbar amyotrophy, stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis .
|
-
-
- HY-169157
-
|
HDAC
|
Neurological Disease
|
HDAC6-IN-50 (Compound 4) is a potent HDAC6 inhibitor with an IC50 of 35 nM. HDAC6-IN-50 can be used for the study of Parkinson's disease (PD) and Alzheimer's disease (AD) research .
|
-
-
- HY-160169
-
-
-
- HY-160169A
-
-
-
- HY-149439
-
-
-
- HY-114616
-
-
-
- HY-19490A
-
(S)-AQW-051
|
nAChR
|
Neurological Disease
|
(S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia .
|
-
-
- HY-40294
-
|
Monoamine Oxidase
GSK-3
LRRK2
|
Cardiovascular Disease
Neurological Disease
Cancer
|
Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases .
|
-
-
- HY-147976
-
|
Glycosidase
|
Neurological Disease
Metabolic Disease
|
Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .
|
-
-
- HY-P2699
-
GrTx; ω-GsTx SIA
|
Calcium Channel
|
Neurological Disease
|
ω-Grammotoxin SIA (GrTx) is P/Q and N-type voltage-gated Calcium channels inhibitor. ω-Grammotoxin SIA is also a protein toxin that can be obtained from spider venom. ω-Grammotoxin SIA has the potential to study neurological diseases as well as cardiovascular diseases .
|
-
-
- HY-148108
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
AChE-IN-27 (compound 8c) is an AChE inhibitor (IC50=0.19 µM). AChE-IN-27 can be used in studies of neurological diseases such as alzheimer's disease, dementia, ataxia and myasthenia gravis .
|
-
-
- HY-W011246
-
HP 029; Hydroxytacrine maleate
|
Cholinesterase (ChE)
|
Neurological Disease
|
Velnacrine maleate (HP 029) is an orally active cholinesterase inhibitor that can be used for the research of Alzheimer's disease .
|
-
-
- HY-157461
-
-
-
- HY-147976A
-
|
Glycosidase
|
Neurological Disease
|
Glucocerebrosidase-IN-1 (compound 11a) hydrochloride is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 hydrochloride can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .
|
-
-
- HY-146068
-
|
Cathepsin
|
Neurological Disease
|
AEP-IN-1 (Compound 13e) is a CNS agent-like non-covalent inhibitor of asparagine endopeptidase (AEP), with the IC50 of 89 nM. AEP-IN-1 can be used for the research of numerous neurological diseases such as Alzheimer’s disease (AD) .
|
-
-
- HY-147577
-
|
TAM Receptor
|
Inflammation/Immunology
Cancer
|
Axl-IN-10 (Example 1) is a potent AXL inhibitor, with an IC50 of 5 nM. Axl-IN-10 has excellent transmembrane properties.Axl-IN-10 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-10 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .
|
-
-
- HY-147576
-
|
TAM Receptor
|
Inflammation/Immunology
Cancer
|
Axl-IN-9 (Example 10) is a potent AXL inhibitor, with an IC50 of 26 nM. Axl-IN-9 has excellent transmembrane properties. Axl-IN-9 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-9 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .
|
-
-
- HY-158334
-
-
-
- HY-137254
-
-
-
- HY-E70413
-
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
Amino acid arylamidase, hog kidney is a metalloprotease that can hydrolyze proteins or peptides containing free α-amino or α-imino groups, playing a crucial role in amino acid metabolism and protein digestion. Its hydrolytic activity can be blocked by acetylation of the N-terminus. Amino acid arylamidase, hog kidney can be used in research on hepatic diseases, biliary diseases, and heart failure .
|
-
-
- HY-107660
-
|
Sirtuin
|
Neurological Disease
|
SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .
|
-
-
- HY-15976
-
|
Others
|
Neurological Disease
|
P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease .
|
-
-
- HY-107337
-
-
-
- HY-P10557
-
|
Biochemical Assay Reagents
|
Neurological Disease
|
DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation .
|
-
-
- HY-P5007
-
|
Biochemical Assay Reagents
|
Cardiovascular Disease
|
Copeptin (human) is a diagnostic and prognostic biomarker for cardiovascular disease (CVD). Copeptin (human) is also the carboxyl terminus of the arginine vasopressin (AVP) precursor peptide. Copeptin (human) can be used in the study of cardiovascular disease .
|
-
-
- HY-144399A
-
|
Transmembrane Glycoprotein
|
Neurological Disease
|
CD33 splicing modulator 1 (Compound 1) hydrochloride is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid cell surface receptor known to regulate microglial activity. CD33 splicing modulator 1 hydrochloride increases exon 2 skipping in the cellular mRNA pool and can be used to study neurodegenerative diseases including Alzheimer's disease .
|
-
-
- HY-144682
-
|
OGA
|
Neurological Disease
|
O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease .
|
-
-
- HY-119238
-
-
-
- HY-48869
-
-
- HY-155830
-
-
- HY-157400
-
|
Monoamine Oxidase
|
Neurological Disease
|
hMAO-B-IN-7 (compound 11n) is a potent and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B), with the IC50 value of 0.79±0.05 μM. hMAO-B-IN-7 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .
|
-
- HY-122210
-
-
- HY-106239
-
-
- HY-P99356
-
BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
-
- HY-168622
-
-
- HY-144399
-
|
Others
|
Neurological Disease
|
CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease .
|
-
- HY-W029600
-
|
Monoamine Oxidase
|
Neurological Disease
|
6,7-Dimethylisatin (compound 1l), an Isatin (HY-Y0265) analogue, is a potent MAO inhibitor with IC50s of 20.3 μM and 6.74 μM for MAO-A and MAO-B, respectively. 6,7-Dimethylisatin has the potential for depression, Alzheimer's disease and Parkinson's disease research .
|
-
- HY-144776
-
|
NAMPT
|
Neurological Disease
Cancer
|
NAT is an initial hit of NAMPT activator. NAMPT is the rate-limiting enzyme in the NAD salvage pathway, which makes it an attractive target for the research of many diseases associated with NAD exhaustion such as neurodegenerative diseases .
|
-
- HY-N11286
-
TG-DHA; Meganol D
|
Others
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .
|
-
- HY-158130
-
|
FKBP
HSP
|
Neurological Disease
Metabolic Disease
Cancer
|
FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the FKBP51-Hsp90 protein-protein interaction, with an IC50 value of 0.1 μM against FKBP51. FKBP51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders .
|
-
- HY-10814
-
|
nAChR
|
Neurological Disease
|
CP-810123 is a brain-permeable agonist of α7 nAChR for the research of cognitive impairment associated with psychiatric or neurological disorders such as schizophrenia and Alzheimer's disease .
|
-
- HY-159888
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
SON38 is a copper chelator capable of chelating divalent copper. SON38 can inhibit the activity of cholinesterases and has potential applications in Alzheimer's disease research .
|
-
- HY-170325
-
|
iGluR
|
Neurological Disease
|
17alpha-Hydroxywithanolide D is the allosteric modulator for NMDA receptor with an IC50 of 44.24 nM. 17alpha-Hydroxywithanolide D exhibits neuroprotective activity and can be used in research of Alzheimer's disease disease .
|
-
- HY-153092
-
BI-685509
|
Guanylate Cyclase
|
Cardiovascular Disease
Metabolic Disease
|
Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .
|
-
- HY-119224
-
|
COMT
|
Neurological Disease
|
BIA 3-335 is an inhibitor for catechol-O-methyltransferase (COMT), and can be used in research about Parkinson's disease .
|
-
- HY-155988
-
-
- HY-153815
-
|
GLP Receptor
|
Metabolic Disease
|
GLP-1 receptor agonist 11 (compound 3) is an agonist of GLP Receptor. GLP-1 receptor agonist 11 can be used in the study of diseases such as diabetes and non-alc. fatty liver disease .
|
-
- HY-16009
-
-
- HY-157806
-
|
α-synuclein
|
Neurological Disease
|
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases .
|
-
- HY-P991045
-
|
Amyloid-β
|
Neurological Disease
|
Donanemab (Mouse IgG2a) (mE8-IgG2a) is a mouse-derived IgG2 monoclonal antibody used in the research of Alzheimer's disease.
|
-
- HY-121340
-
|
Others
|
Neurological Disease
|
Emylcamate is a potent muscle relaxant. Emylcamate has the potential for the research of neurological diseases .
|
-
- HY-153569
-
|
ROCK
|
Others
|
ROCK-IN-7 (compound 9) is a ROCK kinase inhibitor. ROCK-IN-7 can be used for research in ocular diseases (such as glaucoma and retinal diseases) .
|
-
- HY-N2971
-
-
- HY-106938
-
WAY-ACA 147
|
Acyltransferase
|
Cardiovascular Disease
Metabolic Disease
|
Eldacimibe is an ACAT2 inhibitor. Eldacimibe can lower plasma cholesterol levels by blocking cholesterol absorption and can prevent macrophages from turning into foam cells. Eldacimibe can be used in the study of cardiovascular diseases (atherosclerosis), endocrine and metabolic diseases (hypercholesterolemia) .
|
-
- HY-11070
-
-
- HY-106432A
-
SB-202026 hydrochloride; Memric hydrochloride
|
mAChR
|
Neurological Disease
|
Sabcomeline (SB-202026) hydrochloride is a potent and functionally selective muscarinic M1 receptor partial agonist that improve cognition. Sabcomeline hydrochloride can be used for Alzheimer's disease research .
|
-
- HY-106432
-
SB-202026; Memric
|
mAChR
|
Neurological Disease
|
Sabcomeline (SB-202026) is a potent and functionally selective muscarinic M1 receptor partial agonist that improve cognition. Sabcomeline can be used for Alzheimer's disease research .
|
-
- HY-11071
-
-
- HY-164506
-
|
FAAH
|
Neurological Disease
Cancer
|
NRMA-8 is a brain-penetrant small molecule nuclear receptor modulator. NRMA-8 is promising for research of central nervous system disorders, including Alzheimer's disease, Parkinson's disease, demylenation disorders and glioblastomas .
|
-
- HY-158024A
-
-
- HY-B1680
-
-
- HY-103499
-
|
Others
|
Neurological Disease
|
ZK 93426 (hydrochloride) is a benzodiazepine antagonist. ZK 93426 (hydrochloride) can be used for the research of neurological disease .
|
-
- HY-118014
-
-
- HY-149268
-
|
JNK
|
Neurological Disease
|
JNK3 inhibitor-6 (Compound A53) is a selective JNK3 Inhibitor (IC50=78 nM). JNK3 inhibitor-6 has neuroprotective effect, and can used for research of neurodegenerative diseases .
|
-
- HY-156955
-
-
- HY-113639
-
|
Proteasome
|
Neurological Disease
|
A-933548 is a potent and selective inhibitor of calpain, with a Ki of 18 nM. A-933548 can be used for the research of Alzheimer's disease .
|
-
- HY-N7960
-
|
Others
|
Metabolic Disease
|
(2S)-Pteroside A is a pteroside from the rhizomes of subsp. aquilinum of bracken fern, which is promising for research of diabetic diseases .
|
-
- HY-113969
-
|
Endogenous Metabolite
|
Neurological Disease
|
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline (compound 11), a tetrahydroisoquinoline (THIQ) derivative, is a selective phenylethanolamine N-methyltransferase (PNMT) inhibitor with a Ki value of 0.3 μM. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline can be used in research on psychiatric disorders related to Alzheimer's disease and Parkinson's disease .
|
-
- HY-163564
-
|
PROTACs
|
Neurological Disease
Cancer
|
JYQ-194 is a PROTAC degrader targeting human Parkinson's disease protein 7 (PARK7). JYQ-194 can be used in the study of cancer and neurodegenerative diseases. (Pink: PARK7 ligand (HY-163563); Black: linker (HY-W017440); Blue: E3 ligase ligand (HY-10984)) .
|
-
- HY-151536
-
|
Fluorescent Dye
|
Neurological Disease
|
meso-Benzothiazole-BODIPY 505/515 is a boron dipyrromethenes (BODIPY) -based fluorescent probediseases, lysosomal storage diseases and neural degeneration diseases .
|
-
- HY-151338
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
AChE-IN-25 is a potent, selective and uncompetitive acetylcholinesterase (AChE) inhibitor (IC50=2.95 µM). AChE-IN-25 can be used in Alzheimer's disease research .
|
-
- HY-P99491
-
AVTX-007; CERC-007; MEDI 2338
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
|
-
- HY-N2916
-
|
Glutaminase
|
Neurological Disease
|
Barbinervic acid is a glutaminase inhibitor with an IC50 of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases .
|
-
- HY-162027
-
|
HDAC
|
Neurological Disease
|
PB118 is a potent inhibitor of HDAC6 that plays an important role in the pathophysiology of Alzheimer's disease .
|
-
- HY-158794
-
|
Autophagy
|
Neurological Disease
|
Lentztrehalose B is a dehydroxylated analog of trehalose A, possessing antioxidant properties that can be used in research on neurodegenerative diseases and other autophagy-related conditions .
|
-
- HY-142698
-
|
Guanylate Cyclase
|
Cardiovascular Disease
|
SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .
|
-
- HY-155403
-
-
- HY-N11286R
-
|
Others
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
Tridocosahexaenoylglycerol (Standard) is the analytical standard of Tridocosahexaenoylglycerol. This product is intended for research and analytical applications. Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .
|
-
- HY-163885
-
|
Cholinesterase (ChE)
Beta-secretase
γ-secretase
|
Neurological Disease
|
SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice .
|
-
- HY-W017540
-
|
ATP Synthase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
|
-
- HY-50737
-
-
- HY-163358
-
-
- HY-160577
-
|
Liposome
|
Others
|
DOG-IM4 can be used to synthesize nanoparticles to deliver antigen-encoding nucleic acids. It could be used to try to target autoimmune diseases, rare blood or metabolic diseases, allergies, cancer or infectious diseases .
|
-
- HY-13720
-
LY127809 free base
|
Dopamine Receptor
|
Neurological Disease
|
Pergolide (LY127809 (free base)) is an ergot-derived orally active dopamine receptor agonist. Pergolide can be used for Parkinson disease research .
|
-
- HY-135601
-
|
Drug Metabolite
|
Cardiovascular Disease
|
Cinacalcet metabolite M4 is a metabolite of Cinacalcet. Cinacalcet is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease .
|
-
- HY-W763569
-
-
- HY-169328
-
|
Tyrosinase
|
Metabolic Disease
|
Tyrosinase-IN-39 (compound 5r) is a competitive tyrosinase inhibitor with the IC50 of 6.4 μM and can be used for study of skin diseases .
|
-
- HY-123176
-
|
Others
|
Neurological Disease
|
GYKI-13380 is an appetite suppressant. GYKI-13380 has the potential for the research of neurology diseases .
|
-
- HY-156771
-
-
- HY-E70410
-
NAD+ Synthetase; Nicotinamide adenine dinucleotide synthetase
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
NAD synthetase is responsible for the final step in the synthesis of nicotinamide adenine dinucleotide (NAD). The Km values for NAD, ATP, and ammonia of NAD synthetase from Escherichia coli are 200 μM, 11 μM, and 0.65 μM, respectively, while the Km values for NAD, ATP, and ammonia of NAD synthetase from yeast are 170 μM, 190 μM, and 64 μM, respectively. NAD synthetase can be used for enzymatic assays to determine ATP, ammonia, urea, or creatinine, and is also suitable for enzymatic cycling methods. Additionally, NAD synthetase holds potential for research into metabolic diseases, cancer, aging, and neurodegenerative diseases .
|
-
- HY-P10876
-
|
Amyloid-β
|
Neurological Disease
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-148187
-
|
NOD-like Receptor (NLR)
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases .
|
-
- HY-119274
-
|
Others
|
Neurological Disease
|
BN-82451 dihydrochloride, an orally active and CNS-penetrated antioxidant and a multitargeting neuroprotective agent, exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis .
|
-
- HY-105545
-
(+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide
|
mAChR
|
Neurological Disease
|
Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease .
|
-
- HY-P99164
-
LY33003560
|
Microtubule/Tubulin
|
Neurological Disease
|
Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .
|
-
- HY-106000
-
|
Histamine Receptor
|
Neurological Disease
|
GSK239512 is a potent and brain penetrated H3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD) .
|
-
- HY-159133
-
-
- HY-160509
-
-
- HY-156102
-
|
Bcr-Abl
|
Neurological Disease
|
c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .
|
-
- HY-161683
-
|
JAK
|
Neurological Disease
|
Tyk2-IN-19 (compound 1) is an orally active and blood-brain barrier (BBB) permeable Tyk2 inhibitor. Tyk2-IN-19 can be used for study of neurodegenerative diseases .
|
-
- HY-115919
-
-
- HY-90009B
-
-
- HY-154798
-
|
iGluR
|
Neurological Disease
|
AMPA receptor modulator-5 (Example 217) is an AMPA receptor modulator. AMPA receptor modulator-5 can be used for research of neurological disease .
|
-
- HY-W049312
-
7-MEOTA
|
Cholinesterase (ChE)
|
Neurological Disease
|
7-Methoxytacrine (7-MEOTA) is an inhibitor of human acetylcholinesterase (hAChE) with an IC50 value of 10 μM, and can be used for the research of Alzheimer's disease (AD) .
|
-
- HY-163613
-
-
- HY-105157
-
-
- HY-147608
-
|
c-Fms
|
Neurological Disease
|
CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research .
|
-
- HY-100411
-
|
LRRK2
|
Neurological Disease
|
MLi-2 is an orally active and highly selective LRRK2 inhibitor with an IC50 of 0.76 nM. MLi-2 has the potential for Parkinson’s disease .
|
-
- HY-14679
-
|
GSK-3
|
Neurological Disease
|
GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .
|
-
- HY-157751
-
-
- HY-16482
-
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .
|
-
- HY-121949
-
|
COMT
|
Neurological Disease
|
U-0521 is the inhibitor of the catechol-O-methyltransferase (COMT). U-0521 has the potential for the research of Parkinson's disease .
|
-
- HY-N7751
-
|
Others
|
Neurological Disease
|
Isotanshinone II is a natural product that can be isolated from Salvia glutinos. Isotanshinone II can be used to study Alzheimer's disease .
|
-
- HY-159173
-
-
- HY-123227
-
-
- HY-106933A
-
-
- HY-146155
-
|
TRP Channel
|
Metabolic Disease
Inflammation/Immunology
|
TRPC4/5-IN-1 is a potent TRP channel 4/5 (TRPC4/5) inhibitor with IC50s of 2.06 μM and 0.54 μM, respectively. TRPC4/5-IN-1 can be used for proteinuric kidney diseases and skin inflammatory diseases research .
|
-
- HY-135284
-
|
Phosphatase
|
Neurological Disease
Inflammation/Immunology
|
FTY720-Mitoxy is a fingolimod hydrochloride (HY-12005) derivative with neuroprotective and PP2A activating activities. FTY720-Mitoxy has the property of targeting mitochondria. In addition, FTY720-Mitoxy protects neurons by reducing inflammatory responses and is used in the study of neurodegenerative diseases such as Parkinson's disease .
|
-
- HY-147233
-
|
Sirtuin
|
Neurological Disease
|
MIND4-19 is a potent SIRT2 inhibitor with an IC50 value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease .
|
-
- HY-P99527
-
ACC-001; PF 05236806
|
Amyloid-β
|
Neurological Disease
|
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .
|
-
- HY-159691
-
ISIS 463588
|
FGFR
|
Metabolic Disease
|
IONIS-FGFR4Rx (ISIS 463588) is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases .
|
-
- HY-159691A
-
ISIS 463588 sodium
|
FGFR
|
Metabolic Disease
|
IONIS-FGFR4Rx (ISIS 463588) sodium is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases .
|
-
- HY-129660
-
-
- HY-B0590
-
Ro 1-9569
|
Monoamine Transporter
|
Neurological Disease
|
Tetrabenazine (Ro 1-9569) is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .
|
-
- HY-B0590E
-
Ro 1-9569 mesylate
|
Monoamine Transporter
|
Neurological Disease
|
Tetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .
|
-
- HY-106392
-
NB-DGJ; N-(n-Butyl)deoxygalactonojirimycin
|
Glucosylceramide Synthase (GCS)
|
Metabolic Disease
|
Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study .
|
-
- HY-156023
-
-
- HY-149888
-
-
- HY-P4308
-
|
Prolyl Endopeptidase (PREP)
|
Neurological Disease
|
Z-Pro-Pro-aldehyde-dimethyl acetal is a potent inhibitor of prolyl endopeptidase (PREP), a cytoplasmic serine endoprotease (IC50= 12 nM). Z-Pro-Pro-aldehyde-dimethyl acetal plays an important role in cognitive dysfunction in aging and neurodegenerative diseases including Alzheimer's disease .
|
-
- HY-128442
-
Phenyl hydrogen sulfate
|
Endogenous Metabolite
|
Metabolic Disease
|
Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker and future therapeutic target in diabetic kidney disease .
|
-
- HY-132821A
-
E2027 maleate
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases .
|
-
- HY-P1362A
-
Amyloid β Peptide (42-1)(human) TFA
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .
|
-
- HY-N13361
-
|
RAR/RXR
|
Neurological Disease
|
Elodeoidileon A is an agonist for RXRα, that interacts with RXRα-LBD protein with a dissociation constant Kd of 5.85 μM. Elodeoidileon A promotes the expression of ATP-binding cassette transporter A1 (ABCA1). Elodeoidileon A reveals the potential in Alzheimer's disease research .
|
-
- HY-N8260
-
|
Others
|
Neurological Disease
|
Angeloylgomisin Q is a new dibenzocyclooctadiene lignan from the stems of Schisandra sphaerandra . Angeloylgomisin Q has the potential for alzheimer's disease research .
|
-
- HY-149605
-
|
Ketohexokinase
|
Metabolic Disease
|
KHK-IN-4 (compound 14) is a potent ketohexokinase (KHK) inhibitor. KHK-IN-4 can be used for fructose metabolic disease research .
|
-
- HY-W020576
-
NAP 226-90
|
Cholinesterase (ChE)
|
Neurological Disease
|
Rivastigmine metabolite (NAP 226-90) is an acetylcholinesterase (AChE) inhibitor which is produced in kidney. Rivastigmine metabolite is promising for research of Alzheimer’s Disease .
|
-
- HY-69172
-
-
- HY-163498
-
|
NOD-like Receptor (NLR)
|
Neurological Disease
Inflammation/Immunology
|
NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury .
|
-
- HY-163806
-
|
HDAC
|
Neurological Disease
Cancer
|
NT376 is a high potency and selectivity inhibitor of class-IIa Histone deacetylases (HDAC) with an IC50 value of 32 nM, similar to NT160 (HY-149285) (IC50= 46 nM) in HT-29 cells. NT376 is proming for research of various cancers and in the diseases of the central nervous system (CNS) such as Alzheimer’s and Huntington’s diseases .
|
-
- HY-W040146
-
Propiopromazine hydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
Propionylpromazine hydrochloride (Propiopromazine hydrochloride), a dopamine receptor D2 (DRD2) antagonist, can be used in the research of Parkinson disease .
|
-
- HY-N0568
-
Asiaticoside A
|
Endogenous Metabolite
Apoptosis
Autophagy
Keap1-Nrf2
p38 MAPK
Caspase
|
Cardiovascular Disease
Others
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects.
Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB [5][6], exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity . Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.
|
-
- HY-N12581
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
Kuwanon U is a potent cholinesterase inhibitor with IC50s of 19.69, 10.11 µM and Kis of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .
|
-
- HY-143721
-
|
Monoamine Oxidase
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
|
-
- HY-132821
-
-
- HY-148306
-
|
γ-secretase
|
Neurological Disease
|
γ-Secretase modulator 14 is a γ-secretase modulator. γ-Secretase modulator 14 has the potenial for Alzheimer's disease (AD) research (WO2013010904A1; compound 42) .
|
-
- HY-163802
-
-
- HY-168765
-
LSN433771
|
Phospholipase
|
Cardiovascular Disease
|
LY433771 (LSN433771) (Compound 8) is a type X secretory phospholipase A2 (sPLA2) inhibitor with an IC50 value of 3 nM, which can be used in the study of cardiovascular diseases .
|
-
- HY-44154
-
-
- HY-110019A
-
cis-Lu 19-005
|
Drug Derivative
|
Neurological Disease
|
cis-Indatraline (cis-Lu 19-005) hydrochloride is an active compound. cis-Indatraline (cis-Lu 19-005) hydrochloride can be used for the research of neurodegenerative diseases .
|
-
- HY-N13194
-
|
Others
|
Metabolic Disease
|
(2R)-Pteroside B is a pterosin-associated glycoside from the rhizomes of subsp. aquilinum of bracken fern, which is promising for research of diabetic diseases .
|
-
- HY-169627
-
|
VEGFR
|
Cardiovascular Disease
|
VEGFR-IN-7 (Compound 2) is a VEGFR inhibitor, showing inhibition of angiogenesis to a lesser extent. VEGFR-IN-7 is promising for research of cardiovascular diseases .
|
-
- HY-147134
-
|
GSK-3
|
Neurological Disease
|
GSK-3β inhibitor 10 (compound 14a) is a highly potent GSK-3β inhibitor with an IC50 value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .
|
-
- HY-B1786A
-
|
γ-secretase
Amyloid-β
|
Neurological Disease
|
(E/Z)-Sulindac sulfide is a potent γ-secretase modulator (GSM). (E/Z)-Sulindac sulfide selectively reduces Aβ42 production in favor of shorter Aβ species. (E/Z)-Sulindac sulfide can be used for researching Alzheimer’s disease .
|
-
- HY-W184837
-
KR-1008
|
Calcium Channel
|
Cardiovascular Disease
|
m-Nisoldipine (KR-1008) is a dihydropyridine calcium antagonist that can significantly increase cardiac output and heart index, significantly reduce the negative inotropic effect on the myocardium, and has a relatively high selectivity for the thoracic aorta. m-Nisoldipine can be used in the research of cardiovascular diseases .
|
-
- HY-146530
-
|
Others
|
Neurological Disease
Cancer
|
c-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54) .
|
-
- HY-146528
-
|
Others
|
Neurological Disease
Cancer
|
c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50) .
|
-
- HY-153595
-
|
DAPK
|
Cardiovascular Disease
|
DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases .
|
-
- HY-P3244
-
|
Amyloid-β
|
Neurological Disease
|
D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC50 of 2.6 μM, that can be used in Alzheimer's disease study .
|
-
- HY-P3392A
-
ION373 sodium
|
FAP
|
Neurological Disease
|
Zilganersen sodium is a glial fibrillary acidic protein (GFAP) inhibitor. Zilganersen sodium can be used in Alexander disease (AxD) research .
|
-
- HY-119921
-
-
- HY-113303
-
|
Endogenous Metabolite
|
Neurological Disease
Cancer
|
FAPy-adenine is an oxidized DNA base. Fapy-adenine shows an increased trend levels in the Alzheimer's disease brain. Oxidized nucleosides are biochemical markers for tumors, aging, and neurodegenerative diseases .
|
-
- HY-143723
-
|
Monoamine Oxidase
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
|
-
- HY-116072
-
|
Calcium Channel
|
Cardiovascular Disease
|
Antiarrhythmic agent-2 is a nonspecific Ca 2+ inward current blocker that inhibits ionic currents in sensory neuron membranes. Antiarrhythmic agent-2 can be used in the study of cardiovascular diseases, such as arrhythmias .
|
-
- HY-158338
-
|
MAGL
|
Others
Neurological Disease
Inflammation/Immunology
Cancer
|
ABHD antagonist 1 possesses ABHD6 (α/β-Hydrolase domain containing 6) inhibitory activity, involving the regulation of biochemical pathways involved in ABHD6, thereby affecting cell function and inflammatory response. ABHD antagonist 1 can be used in pain, neuropathic diseases, inflammatory diseases. Autoimmune diseases, metabolic diseases, and cancer research .
|
-
- HY-148382
-
-
- HY-109055
-
E2609
|
Beta-secretase
|
Neurological Disease
|
Elenbecestat (E2609) is a potent, orally bioavailable and CNS-penetrant BACE-1 inhibitor. Elenbecestat has the potential for Alzheimer's disease (AD) research .
|
-
- HY-122908
-
AZD5718
|
FLAP
|
Cardiovascular Disease
|
Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5?Lipoxygenase activating protein), with an IC50 of 2 nM. Atuliflapon is used in the study for coronary artery disease .
|
-
- HY-N7745
-
Glucopsychosine; Lyso-Gb1
|
Others
|
Metabolic Disease
|
Glucosylsphingosine (lyso-Gb1) is a deacylated form of glucosylceramide and is also degraded by the glucocerebrosidase. Glucosylsphingosine is a very promising, reliable and specific biomarker for monitoring Gaucher disease .
|
-
- HY-119889
-
|
Sirtuin
|
Neurological Disease
|
A1B11 is a selective SIRT inhibitor (SIRT2:IC50=5.3 μM) that can be used in the study of neurodegenerative diseases .
|
-
- HY-10594
-
TAK-442
|
Factor Xa
|
Cardiovascular Disease
Inflammation/Immunology
|
Letaxaban (TAK-442) is an orally active and selective direct FXa inhibitor. Letaxaban is a drug with dual anticoagulant and anti-inflammatory activity that works by directly inhibiting FXa and by intervening in the PAR1 signaling pathway. Letaxaban can be used in the study of thrombotic diseases, cardiovascular diseases and inflammation-related diseases .
|
-
- HY-153057
-
|
Histone Methyltransferase
|
Metabolic Disease
Cancer
|
PRMT5-IN-46 (compound 278) inhibits PRMT5 with IC50 of 1-10 μM. PRMT5 is a methyltransferase which is associated with specific genetic alterations. PRMT5-IN-46 can be used to treat proliferative diseases, metabolic disorders, and blood diseases.
|
-
- HY-162246
-
|
Sodium Channel
|
Cardiovascular Disease
Neurological Disease
|
Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research .
|
-
- HY-144764
-
|
5-HT Receptor
|
Neurological Disease
|
5-HT1A antagonist 1 (compound 6f) is a potent and selective antagonist of 5-HT1A receptor, with a Ki of 35 nM. 5-HT1A antagonist 1 can be used for the research of CNS diseases .
|
-
- HY-113745
-
|
Others
|
Neurological Disease
|
LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia .
|
-
- HY-147574
-
|
TAM Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease .
|
-
- HY-W017500
-
|
iGluR
|
Neurological Disease
|
N-Methyl-DL-aspartic acid is a glutamate analogue and a NMDA receptor agonist and can be used for neurological diseases research .
|
-
- HY-101321
-
-
- HY-120644
-
-
- HY-P0128F1
-
|
Amyloid-β
|
Neurological Disease
|
FITC-β-Ala-β-Amyloid (25-35) is a fluorescent product labeled by FITC that can be used in Alzheimer's disease research .
|
-
- HY-17387
-
Huperzine A
|
Cholinesterase (ChE)
Apoptosis
iGluR
|
Neurological Disease
|
(-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC50 of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .
|
-
- HY-148475
-
-
- HY-103424
-
|
Dopamine Receptor
|
Neurological Disease
|
A-412997 dihydrochloride is a selective dopamine D4 receptor agonist. A-412997 dihydrochloride improves cognitive performance in rats and can be used in the research of psychiatric diseases .
|
-
- HY-164341
-
|
Tau Protein
|
Neurological Disease
|
TAU-IN-2 (Example 25) is a TAU inhibitor with an EC50 value of 7.7 nM. TAU-IN-2 can be used in the study of neurodegenerative diseases .
|
-
- HY-153279
-
-
- HY-117512
-
|
Dopamine Transporter
Serotonin Transporter
|
Neurological Disease
|
UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC50 values of 3.6 µM and 2.3 µM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease .
|
-
- HY-156961
-
|
JAK
|
Inflammation/Immunology
|
GLPG3667 is a small molecule inhibitor of TYK2. GLPG3667 plays an important role in inflammatory diseases and/or diseases associated with hypersecretion of IFNa and/or interferons .
|
-
- HY-133589
-
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
Fulvine is a pyrrolizidine alkaloid isolated from the seeds of Crotalaria fulva. Fulvine is hepatotoxic and can be used to induce hypertensive pulmonary vascular disease in vivo .
|
-
- HY-13720S
-
-
- HY-169334
-
|
Endogenous Metabolite
|
Metabolic Disease
|
BDK-IN-1 (compound (-)-43) is a BDK inhibitor with the IC50 of 0.23 μM and the max inhibition of 90%. BDK-IN-1 decreases the level of phospho-E1 and can be used for study of cardiometabolic diseases .
|
-
- HY-W355779
-
Tyrosylprolylglutaminylprolylglutamine
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
Gliadins (Tyrosylprolylglutaminylprolylglutamine) comprise a family of glutamine- and proline-rich monomeric proteins that plays an role in autoimmune disease, such as celiac disease .
|
-
- HY-N12019
-
-
- HY-136733
-
Ac-Asp-Asn-Leu-Asp-CHO
|
Caspase
|
Infection
Neurological Disease
|
Ac-DNLD-CHO (Ac-Asp-Asn-Leu-Asp-CHO) is a Caspase-3/7 inhibitor (IC50: 9.89, 245 nM respectively; Ki app: 0.68, 55.7 nM respectively). Ac-DNLD-CHO can be used for research of caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases .
|
-
- HY-120419
-
|
Monoamine Oxidase
|
Neurological Disease
|
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-W471937
-
-
- HY-146478
-
|
Adenosine Receptor
|
Neurological Disease
Inflammation/Immunology
|
A1/A3 AR antagonist 1 (compound 10) is a potent adenosine 1 (A1) and adenosine 3 (A3) receptor dual antagonist with Kis of 36.7 nM, 25.4 nM and 1.47 nM for human A1, human A3 and rat A1, respectively. A1/A3 AR antagonist 1 can be used for researching kidney failure, inflammatory pulmonary diseases, and Alzheimer’s disease .
|
-
- HY-145317
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-2 (compoubd 22) is a potent, selective, orally active and brain-penetrant inhibitor LRRK2, with IC50 of <0.6 nM. LRRK2-IN-2 can be used for the research of Parkinson's disease .
|
-
- HY-P5334A
-
|
Tau Protein
|
Neurological Disease
|
AADvac 1 TFA is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 TFA is composed of a regulatory peptide 294KDNIKHVPGGGS 305 that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide .
|
-
- HY-B1363
-
Bendrofluazide
|
Others
|
Cardiovascular Disease
|
Bendroflumethiazide is an orally active diuretic. Bendroflumethiazide is an antihypertensive agent. Bendroflumethiazide has the potential for the research of arterial hypertensive disease .
|
-
- HY-146958
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-8 is a potent reversible MAO-B inhibitor and an inhibitor of microglial production of neuroinflammatory mediator. MAO-B-IN-8 can be used for neurodegenerative disease research .
|
-
- HY-N0568R
-
|
Endogenous Metabolite
Apoptosis
Autophagy
Keap1-Nrf2
p38 MAPK
Caspase
|
Cardiovascular Disease
Others
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
Madecassoside (Standard) is the analytical standard of Madecassoside. This product is intended for research and analytical applications. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects.
Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB , exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity[10]. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.
|
-
- HY-148132
-
|
GSK-3
|
Neurological Disease
|
GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .
|
-
- HY-152111
-
-
- HY-P10861
-
|
Tau Protein
|
Neurological Disease
|
RI-AG03 is an orally active and a BBB-penatrable Tau aggregation peptide inhibitor. RI-AG03 inhibits Tau aggregation and improves associated neurodegeneration and behavioral phenotypes in both in vivo and in vitro models. RI-AG03 can be used in the study of tauopathies such as Alzheimer's disease .
|
-
- HY-108237
-
(+)-PHNO; Dopazinol
|
Dopamine Receptor
|
Neurological Disease
|
Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD) .
|